The Inflation Reduction Act (IRA) continues to reshape the U.S. pharmaceutical market. After the first list of 10 Medicare Part D drugs entered negotiations in 2023, the clock is now ticking toward Phase 2, when the next set of drugs will be named for 2026... Continue reading
Return to previous page
Tag: Global Launch Strategy
More
More
- Report & Insights
- Strategy Products
Strategy Products
- Consulting Services
- Media
Media
